Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left">Year</td><td class="align_center">Years 1–3</td><td class="align_center">Year 4</td><td class="align_center">Year 5</td><td class="align_center">Total cost</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left">Average cost</td><td class="align_center">€125,783</td><td class="align_center">€41,190</td><td class="align_center">€41,190</td><td class="align_center">€208,163</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Total cost of CDLCI over five years of treatment.</div>

Parkinson’s Disease

tab4

Table 4

Table 4: Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies 